Copyright Reports & Markets. All rights reserved.

Dynamics in Post-pandemic Global Cancer Antibody Drug Conjugates Industry: Supply and Demand, Markets and Prices 2021-2027

Request for Sample of this report
Buy now

Table of Contents

    1 Product Introduction and Overview

    • 1.1 Product Definition
    • 1.2 Product Specification
    • 1.3 Global Market Overview
      • 1.3.1 Global Cancer Antibody Drug Conjugates Market Status and Forecast (2016-2027)
      • 1.3.2 Global Cancer Antibody Drug Conjugates Sales Value CAGR by Region
    • 1.4 Market Drivers, Inhibitors
      • 1.4.1 Market Drivers
      • 1.4.2 Market Inhibitors
      • 1.4.3 COVID-19 Impact Analysis

    2 Global Cancer Antibody Drug Conjugates Supply by Company

    • 2.1 Global Cancer Antibody Drug Conjugates Sales Volume by Company
    • 2.2 Global Cancer Antibody Drug Conjugates Sales Value by Company
    • 2.3 Global Cancer Antibody Drug Conjugates Price by Company
    • 2.4 Cancer Antibody Drug Conjugates Production Location and Sales Area of Main Manufacturers
    • 2.5 Trend of Concentration Rate

    3 Global and Regional Cancer Antibody Drug Conjugates Market Status by Category

    • 3.1 Cancer Antibody Drug Conjugates Category Introduction
      • 3.1.1 First & Second Generation ADCs
      • 3.1.2 Third Generation ADCs
    • 3.2 Global Cancer Antibody Drug Conjugates Market by Category
      • 3.2.1 Global Cancer Antibody Drug Conjugates Sales Volume by Category (2016-2021)
      • 3.2.2 Global Cancer Antibody Drug Conjugates Sales Value by Category (2016-2021)
      • 3.2.3 Global Cancer Antibody Drug Conjugates Price by Category (2016-2021)
    • 3.3 North America: by Category
    • 3.4 Europe: by Category
    • 3.5 Asia Pacific: by Category
    • 3.6 Central & South America: by Category
    • 3.7 Middle East & Africa: by Category

    4 Global and Regional Cancer Antibody Drug Conjugates Market Status by End User/Segment

    • 4.1 Cancer Antibody Drug Conjugates Segment by End User/Segment
      • 4.1.1 Hospitals
      • 4.1.2 Clinics
      • 4.1.3 Others
    • 4.2 Global Cancer Antibody Drug Conjugates Market by End User/Segment
      • 4.2.1 Global Cancer Antibody Drug Conjugates Sales Volume by End User/Segment (2016-2021)
      • 4.2.2 Global Cancer Antibody Drug Conjugates Sales Value by End User/Segment (2016-2021)
      • 4.2.3 Global Cancer Antibody Drug Conjugates Price by End User/Segment (2016-2021)
    • 4.3 North America: by End User/Segment
    • 4.4 Europe: by End User/Segment
    • 4.5 Asia Pacific: by End User/Segment
    • 4.6 Central & South America: by End User/Segment
    • 4.7 Middle East & Africa: by End User/Segment

    5 Global Cancer Antibody Drug Conjugates Market Status by Region

    • 5.1 Global Cancer Antibody Drug Conjugates Market by Region
      • 5.1.1 Global Cancer Antibody Drug Conjugates Sales Volume by Region
      • 5.1.2 Global Cancer Antibody Drug Conjugates Sales Value by Region
    • 5.2 North America Cancer Antibody Drug Conjugates Market Status
    • 5.3 Europe Cancer Antibody Drug Conjugates Market Status
    • 5.4 Asia Pacific Cancer Antibody Drug Conjugates Market Status
    • 5.5 Central & South America Cancer Antibody Drug Conjugates Market Status
    • 5.6 Middle East & Africa Cancer Antibody Drug Conjugates Market Status

    6 North America Cancer Antibody Drug Conjugates Market Status

    • 6.1 North America Cancer Antibody Drug Conjugates Market by Country
      • 6.1.1 North America Cancer Antibody Drug Conjugates Sales Volume by Country (2016-2021)
      • 6.1.2 North America Cancer Antibody Drug Conjugates Sales Value by Country (2016-2021)
    • 6.2 United States
    • 6.3 Canada
    • 6.4 Mexico

    7 Europe Cancer Antibody Drug Conjugates Market Status

    • 7.1 Europe Cancer Antibody Drug Conjugates Market by Country
      • 7.1.1 Europe Cancer Antibody Drug Conjugates Sales Volume by Country (2016-2021)
      • 7.1.2 Europe Cancer Antibody Drug Conjugates Sales Value by Country (2016-2021)
    • 7.2 Germany
    • 7.3 France
    • 7.4 UK
    • 7.5 Italy
    • 7.6 Russia
    • 7.7 Spain

    8 Asia Pacific Cancer Antibody Drug Conjugates Market Status

    • 8.1 Asia Pacific Cancer Antibody Drug Conjugates Market by Country
      • 8.1.1 Asia Pacific Cancer Antibody Drug Conjugates Sales Volume by Country (2016-2021)
      • 8.1.2 Asia Pacific Cancer Antibody Drug Conjugates Sales Value by Country (2016-2021)
    • 8.2 China
    • 8.3 Japan
    • 8.4 Korea
    • 8.5 Southeast Asia
    • 8.6 India
    • 8.7 Australasia

    9 Central & South America Cancer Antibody Drug Conjugates Market Status

    • 9.1 Central & South America Cancer Antibody Drug Conjugates Market by Country
      • 9.1.1 Central & South America Cancer Antibody Drug Conjugates Sales Volume by Country (2016-2021)
      • 9.1.2 Central & South America Cancer Antibody Drug Conjugates Sales Value by Country (2016-2021)
    • 9.2 Brazil
    • 9.3 Argentina
    • 9.4 Colombia

    10 Middle East & Africa Cancer Antibody Drug Conjugates Market Status

    • 10.1 Middle East & Africa Cancer Antibody Drug Conjugates Market by Country
      • 10.1.1 Middle East & Africa Cancer Antibody Drug Conjugates Sales Volume by Country (2016-2021)
      • 10.1.2 Middle East & Africa Cancer Antibody Drug Conjugates Sales Value by Country (2016-2021)
    • 10.2 Iran
    • 10.3 Israel
    • 10.4 Turkey
    • 10.5 South Africa
    • 10.8 Saudi Arabia

    11 Supply Chain and Manufacturing Cost Analysis

    • 11.1 Supply Chain Analysis
    • 11.2 Production Process Chart Analysis
    • 11.3 Raw Materials and Key Suppliers Analysis
      • 11.3.1 Raw Materials Introduction
      • 11.3.2 Raw Materials Key Suppliers List
    • 11.4 Cancer Antibody Drug Conjugates Manufacturing Cost Analysis
    • 11.5 Cancer Antibody Drug Conjugates Sales Channel and Distributors Analysis
      • 11.5.1 Cancer Antibody Drug Conjugates Sales Channel
      • 11.5.2 Cancer Antibody Drug Conjugates Distributors
    • 11.6 Cancer Antibody Drug Conjugates Downstream Major Buyers

    12 Global Cancer Antibody Drug Conjugates Market Forecast by Category and by End User/Segment

    • 12.1 Global Cancer Antibody Drug Conjugates Sales Volume and Sales Value Forecast (2022-2027)
    • 12.2 Global Cancer Antibody Drug Conjugates Forecast by Category
      • 12.2.1 Global Cancer Antibody Drug Conjugates Sales Volume Forecast by Category
      • 12.2.2 Global Cancer Antibody Drug Conjugates Sales Value Forecast by Category
      • 12.2.3 Global Cancer Antibody Drug Conjugates Price Forecast by Category
    • 12.3 Global Cancer Antibody Drug Conjugates Forecast by End User/Segment
      • 12.3.1 Global Cancer Antibody Drug Conjugates Sales Volume Forecast by End User/Segment
      • 12.3.2 Global Cancer Antibody Drug Conjugates Sales Value Forecast by End User/Segment
      • 12.3.3 Global Cancer Antibody Drug Conjugates Price Forecast by End User/Segment

    13 Global Cancer Antibody Drug Conjugates Market Forecast by Region/Country

    • 13.1 Global Cancer Antibody Drug Conjugates Market Forecast by Region (2022-2027)
      • 13.1.1 Global Cancer Antibody Drug Conjugates Sales Volume Forecast by Region (2022-2027)
      • 13.1.2 Global Cancer Antibody Drug Conjugates Sales Value Forecast by Region (2022-2027)
    • 13.2 North America Market Forecast
    • 13.3 Europe Market Forecast
    • 13.4 Asia Pacific Market Forecast
    • 13.5 Central & South America Market Forecast
    • 13.6 Middle East & Africa Market Forecast

    14 Key Participants Company Information

    • 14.1 Viventia Biotechnologies
      • 14.1.1 Company Information
      • 14.1.2 Cancer Antibody Drug Conjugates Product Introduction
      • 14.1.3 Viventia Biotechnologies Cancer Antibody Drug Conjugates Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.1.4 SWOT Analysis
    • 14.2 UCB
      • 14.2.1 Company Information
      • 14.2.2 Cancer Antibody Drug Conjugates Product Introduction
      • 14.2.3 UCB Cancer Antibody Drug Conjugates Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.2.4 SWOT Analysis
    • 14.3 Stem CentRx
      • 14.3.1 Company Information
      • 14.3.2 Cancer Antibody Drug Conjugates Product Introduction
      • 14.3.3 Stem CentRx Cancer Antibody Drug Conjugates Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.3.4 SWOT Analysis
    • 14.4 Seattle Genetics
      • 14.4.1 Company Information
      • 14.4.2 Cancer Antibody Drug Conjugates Product Introduction
      • 14.4.3 Seattle Genetics Cancer Antibody Drug Conjugates Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.4.4 SWOT Analysis
    • 14.5 Roche
      • 14.5.1 Company Information
      • 14.5.2 Cancer Antibody Drug Conjugates Product Introduction
      • 14.5.3 Roche Cancer Antibody Drug Conjugates Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.5.4 SWOT Analysis
    • 14.6 Progenics Pharmaceuticals
      • 14.6.1 Company Information
      • 14.6.2 Cancer Antibody Drug Conjugates Product Introduction
      • 14.6.3 Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.6.4 SWOT Analysis
    • 14.7 PDL BioPharma
      • 14.7.1 Company Information
      • 14.7.2 Cancer Antibody Drug Conjugates Product Introduction
      • 14.7.3 PDL BioPharma Cancer Antibody Drug Conjugates Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.7.4 SWOT Analysis
    • 14.8 Novartis
      • 14.8.1 Company Information
      • 14.8.2 Cancer Antibody Drug Conjugates Product Introduction
      • 14.8.3 Novartis Cancer Antibody Drug Conjugates Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.8.4 SWOT Analysis
    • 14.9 Nordic Nanovector
      • 14.9.1 Company Information
      • 14.9.2 Cancer Antibody Drug Conjugates Product Introduction
      • 14.9.3 Nordic Nanovector Cancer Antibody Drug Conjugates Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.9.4 SWOT Analysis
    • 14.10 Millennium
      • 14.10.1 Company Information
      • 14.10.2 Cancer Antibody Drug Conjugates Product Introduction
      • 14.10.3 Millennium Cancer Antibody Drug Conjugates Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.10.4 SWOT Analysis
    • 14.11 Merck
    • 14.12 Helix BioPharma
    • 14.13 Bristol-Myers Squibb
    • 14.14 Biotest AG
    • 14.15 Biogen Idec
    • 14.16 AbGenomics Corporation
    • 14.17 AbbVie

    15 Conclusion

      16 Methodology

      Covid-19 has impacted the supply and demand status for many industries along the supply chain. In this report a comprehensive analysis of current global Cancer Antibody Drug Conjugates market in terms of demand and supply environment is provided, as well as price trend currently and in the next few years. Global leading players are profiled with their revenue, market share, profit margin, major product portfolio and SWOT analysis. From industry perspective this report analyses supply chain, including process chart introduction, upstream key raw material and cost analysis, distributor and downstream buyer analysis. This report also includes global and regional market size and forecast, major product development trend and typical downstream segment scenario, under the context of market drivers and inhibitors analysis. According to this survey, the global Cancer Antibody Drug Conjugates market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million in 2027.

      Segmented by Category
      First & Second Generation ADCs
      Third Generation ADCs

      Segmented by End User/Segment
      Hospitals
      Clinics
      Others

      Segmented by Country
      North America
      United States
      Canada
      Mexico
      Europe
      Germany
      France
      UK
      Italy
      Russia
      Spain
      Asia Pacific
      China
      Japan
      Korea
      Southeast Asia
      India
      Australasia
      Central & South America
      Brazil
      Argentina
      Colombia
      Middle East & Africa
      Iran
      Israel
      Turkey
      South Africa
      Saudi Arabia

      Key manufacturers included in this survey
      Viventia Biotechnologies
      UCB
      Stem CentRx
      Seattle Genetics
      Roche
      Progenics Pharmaceuticals
      PDL BioPharma
      Novartis
      Nordic Nanovector
      Millennium
      Merck
      Helix BioPharma
      Bristol-Myers Squibb
      Biotest AG
      Biogen Idec
      AbGenomics Corporation
      AbbVie
      Buy now